India, July 29 -- While reporting financial results for the second quarter on Tuesday, biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, raised its adjusted earnings and sales guidance for the full-year 2025.
For fiscal 2025, Merck now projects adjusted earnings in a range of $8.87 to $8.97 per share on sales between $64.3 billion and $65.3 billion. Previously, the company expected adjusted earnings in a range of $8.82 to $8.97 per share on sales between $64.1 billion and $65.6 billion.
On average, analysts polled expect the company to report earnings of $8.87 per share on sales of $64.93 billion for the year. Analysts' estimates typically exclude special items.
The company said the $200 million...